scholarly journals Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials

2010 ◽  
Vol 34 (2) ◽  
pp. 117-123 ◽  
Author(s):  
Lei Zhang ◽  
Shuning Zhang ◽  
Hong Jiang ◽  
Aijun Sun ◽  
Yunzeng Zou ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiac Function ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Statin Treatment ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Xiaolong Song ◽  
Huiyan Qu ◽  
Zongguo Yang ◽  
Jingfeng Rong ◽  
Wan Cai ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Serum Levels ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled

Background. Whether additional benefit can be achieved with the use of L-carnitine (L-C) in patients with chronic heart failure (CHF) remains controversial. We therefore performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of L-C treatment in CHF patients. Methods. Pubmed, Ovid Embase, Web of Science, and Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) database, Wanfang database, Chinese Biomedical (CBM) database, and Chinese Science and Technology Periodicals database (VIP) until September 30, 2016, were identified. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently. Results. 17 RCTs with 1625 CHF patients were included in this analysis. L-C treatment in CHF was associated with considerable improvement in overall efficacy (OR = 3.47, P<0.01), left ventricular ejection fraction (LVEF) (WMD: 4.14%, P=0.01), strike volume (SV) (WMD: 8.21 ml, P=0.01), cardiac output (CO) (WMD: 0.88 L/min, P<0.01), and E/A (WMD: 0.23, P<0.01). Moreover, treatment with L-C also resulted in significant decrease in serum levels of BNP (WMD: −124.60 pg/ml, P=0.01), serum levels of NT-proBNP (WMD: −510.36 pg/ml, P<0.01), LVESD (WMD: −4.06 mm, P<0.01), LVEDD (WMD: −4.79 mm, P<0.01), and LVESV (WMD: −20.16 ml, 95% CI: −35.65 to −4.67, P<0.01). However, there were no significant differences in all-cause mortality, 6-minute walk, and adverse events between L-C and control groups. Conclusions. L-C treatment is effective for CHF patients in improving clinical symptoms and cardiac functions, decreasing serum levels of BNP and NT-proBNP. And it has a good tolerance.

Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials

2009 ◽  
Vol 158 (3) ◽  
pp. 422-430 ◽  
Author(s):  
G. Michael Felker ◽  
Vic Hasselblad ◽  
Adrian F. Hernandez ◽  
Christopher M. O'Connor
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Guided Therapy

SSRIs versus exercise training for depression in chronic heart failure: A meta-analysis of randomized controlled trials

2013 ◽  
Vol 168 (5) ◽  
pp. 4956-4958 ◽  
Author(s):  
Lampros Samartzis ◽  
Stavros Dimopoulos ◽  
Maria Tziongourou ◽  
Eleni Koroboki ◽  
Theodoros Kyprianou ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Exercise Training ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document